- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.10. | Morgan Stanley initiates ADARx stock with overweight rating | 1 | Investing.com | ||
| 20.10. | Morgan Stanley startet Beobachtung von ADARx Pharmaceuticals mit "Overweight" | 2 | Investing.com Deutsch | ||
| 20.10. | TD Cowen initiates ADARx stock with buy rating on siRNA tech | 1 | Investing.com | ||
| ADARX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 20.10. | TD Cowen startet Beobachtung von ADARx mit "Buy" - Potenzial durch siRNA-Technologie der nächsten Generation | 1 | Investing.com Deutsch | ||
| 01.10. | ADARx erzielt nach Ausübung der Mehrzuteilungsoption Bruttoerlöse von 513,2 Mio. US-Dollar | 1 | Investing.com Deutsch | ||
| 01.10. | ADARx raises $513.2M as underwriters exercise IPO option | 1 | Investing.com | ||
| 01.10. | ADARx Pharmaceuticals Inc.: ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering | 266 | GlobeNewswire (Europe) | SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx) (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced... ► Artikel lesen | |
| 28.09. | Can AbbVie's Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation? | 20 | Insider Monkey | ||
| 28.09. | ADARx Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.09. | HBM Healthcare Investments Raises Stake In ADARx Pharma | 5 | RTTNews | ||
| 28.09. | HBM Healthcare Investments AG: HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs | 738 | EQS Group (DE) | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs... ► Artikel lesen | |
| 25.09. | ADARx Pharmaceuticals surges following upsized IPO | 2 | Seeking Alpha | ||
| 25.09. | Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut | 2 | MedCity News | ||
| 25.09. | Adarx Pharmaceuticals: 55 % des Börsengangs an nur zehn Investoren zugeteilt | 3 | Investing.com Deutsch | ||
| 25.09. | ADARx Pharmaceuticals raises $446.3 million in upsized US IPO | 1 | Reuters | ||
| 25.09. | siRNA biotech ADARx Pharmaceuticals prices upsized IPO at $17, the high end of the range | 2 | Renaissance Capital | ||
| 25.09. | ADARx scores upsized $446M IPO, while fellow RNA biotech City Therapeutics maps out Nasdaq plans | 3 | FierceBiotech | ||
| 25.09. | RNAi drug specialist ADARx raises $446M IPO | 1 | BioPharma Dive | ||
| 25.09. | ADARx Pharmaceuticals prices upsized IPO at $17 per share | 1 | Investing.com | ||
| 25.09. | ADARx Pharmaceuticals Inc.: ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering | 558 | GlobeNewswire (Europe) | SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
Das Unternehmen ADARX PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 13,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADARX PHARMACEUTICALS INC finden Sie auf Wallstreet Online.